NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals announced this week that it has initiated a Phase I trial of its RNAi-based hepatitis B therapy TKM-HBV, a key milestone for the company as it prepares to merge with HBV drug firm OnCore BioPharma.

TKM-HBV comprises siRNAs targeting several sites on the HBV genome and is delivered using Tekmira's lipid nanoparticles (LNPs). In preclinical testing, the drug has been shown to trigger reductions in HBV surface antigen, a key indicator of active infection, as well as cccDNA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.